探讨适应性披露技术对减轻退伍军人创伤后应激障碍症状严重程度的影响:一项随机对照试验的研究方案
该随机对照试验将在伊朗亚苏季招募58名退伍军人(每组29人),评估适应性披露(AD)对创伤后应激障碍(PTSD)症状严重程度的影响。干预组接受每周一次共6次、每次90分钟的AD治疗,对照组在此期间不接受干预。主要结局采用PTSD检查表民用版(PCL-C)测量。
要点
- 适应性披露(AD)是一种针对战斗相关PTSD的新型情绪聚焦认知行为疗法,包含暴露疗法和空椅技术。
- 该试验将纳入58名退伍军人,干预组接受6次每周90分钟的AD治疗,对照组暂不接受干预。
- 主要结局为PTSD症状严重程度,采用PTSD检查表民用版(PCL-C)测量。
核心结论
- 该研究预期为AD对退伍军人PTSD的疗效提供重要见解,若成功可为医疗指南提供参考并帮助精神科护士减轻症状。
- 该研究将提供AD在伊朗退伍军人群体中疗效的首个实证证据。
研究设计与样本
- 随机对照试验,计划招募58名退伍军人(每组29人),通过方便抽样从亚苏季的Shahid Rajaee和Salman医院招募。
- 纳入标准:18岁及以上退伍军人、确诊PTSD、经精神状态检查具备接受AD的足够自知力、签署知情同意。
- 排除标准:严重精神障碍(如精神病性或双相I型)、近3个月内有自杀/杀人意念、同时接受系统性创伤聚焦治疗。
- 干预组接受每周一次共6次、每次90分钟的AD治疗;对照组在此期间不接受干预,研究结束后对照组也接受AD技术教育。
关键数值与推荐
- 主要结局为PTSD症状严重程度,采用PTSD检查表民用版(PCL-C)测量,该量表为17项自评量表。
- 数据使用SPSS版本27进行分析。
- 试验注册号:IRCT20160815029377N4,注册日期2025年3月5日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-traumatic stress disorder (PTSD) presents significant mental health challenges for veterans, leading to substantial physical, cognitive, and psychological difficulties, including heightened risks of social issues and suicidal ideation. Adaptive Disclosure (AD) is a novel, emotion-focused Cognitive Behavioral Therapy (CBT) approach developed by the military for combat-related PTSD. This technique involves exposure therapy and an empty-chair technique, allowing patients to verbalize unresolved issues. Despite its short, six-session duration, AD appears well-tolerated and effective in reducing PTSD symptoms. Given the limited global studies and their absence in Iran, this study will be conducted to investigate AD's impact on reducing PTSD symptom severity in veterans. METHODS: This randomized clinical trial will explore AD's effect on PTSD symptom severity. A total of 58 participants (29 per group) will be recruited via available sampling from Shahid Rajaee and Salman Hospitals in Yasuj. Participants must be veterans aged 18 or older, with diagnosed PTSD, sufficient insight for AD (assessed via Mental Status Exam), and informed consent. Exclusions include severe mental disorders (e.g., psychotic or bipolar type I), recent suicidal/homicidal ideation (within 3 months), or concurrent systematic trauma-focused therapies. The intervention group will receive six weekly 90-min AD sessions. The control group will receive no intervention during this period. Immediately after the intervention, both groups will complete the research questionnaire. Following the study, the control group will also be offered education on the Adaptive Disclosure technique. The primary outcome, severity of post-traumatic stress disorder symptoms, will be measured using the Post-Traumatic Stress Disorder Checklist- Civilian Version (PCL-C), a 17-item self-report scale. Data will be analyzed with SPSS version 27. Ethical approval has been secured from Yasuj University of Medical Sciences (Supplementary File 2). DISCUSSION: The results are expected to offer vital insights into AD's effectiveness for veterans with PTSD. If successful, this approach could inform policymakers for healthcare guidelines and aid psychiatric nurses in symptom alleviation. This research will significantly contribute to the scientific community by providing the first empirical evidence of AD's efficacy in an Iranian veteran population, expanding knowledge on culturally relevant treatments for combat-related PTSD, and potentially informing clinical practices nationally and internationally. TRIAL REGISTRATION: IRCT number IRCT20160815029377N4. Registered on 03/05/2025.
引用
- Malekzadeh M, Afzali SMA, Dasdar S, et al. Exploring the impact of the adaptive disclosure technique on reducing the severity of post-traumatic stress disorder symptoms in veterans: a study protocol for a randomized controlled trial. Trials. 2026. PMID: 41593784. doi:10.1186/s13063-026-09499-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。